trending Market Intelligence /marketintelligence/en/news-insights/trending/WKHjtfsGv9Rfi3h05CaNIg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Akcea seeks EMA approval for rare disorder drug

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Six trends shaping the industries and sectors we cover in 2021


Akcea seeks EMA approval for rare disorder drug

Akcea Therapeutics Inc. filed an application with the European Medicines Agency, seeking approval for a treatment of a rare genetic disorder.

Volanesorsen is meant for patients with the familial chylomicronemia syndrome which results in abdominal pain and potentially fatal bouts of pancreatitis, the inflammation of the pancreas.

Akcea, a unit of Ionis Pharmaceuticals Inc., will also file applications for its drug in Canada and the U.S. in September.